The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Hims & Hers, one of the most popular telehealth services in the world, is in danger of losing one of its central revenue sources. The U.S. Food and Drug Administration (FDA) removed semaglutide ...

Stocks slid Friday as Wall Street’s mood darkened on the heels of soft economic data.The Dow Jones Industrial Average recorded its worst day of the year, closing down 1.7%, while the S&P 500 and ...